Study of Abdominal Color Doppler Ultrasound Combined with CA125 in the Diagnosis of Ovarian Serous Tumors

doi:10.7517/issn.1674-0475.210720

Abstract

Abstract: This study discussed the value of abdominal color ultrasound combined with carbohydrate antigen 125 (CA125) in the diagnosis of ovarian serous tumors. A total of 80 cases of ovarian serous tumor patient were selected, including 23 cases of ovarian serous cystadenoma, 30 cases of serous borderline tumor and 27 cases of serous carcinoma, the differences of ultrasound characteristics and serum CA125 in each group were compared. The proportion of cystic solid echo, blood flow distribution and ascites in patients with serous borderline tumor and serous carcinoma was significantly higher than that in patients with ovarian serous cystadenoma (P<0.05), and the proportion of regular shape and clear boundary was significantly lower than that in patients with ovarian serous cystadenoma (P<0.05). The serum CA125 of serous carcinoma patients was (301.45 ±104.42) U/mL, which was significantly higher than that in patients with serous borderline tumor and ovarian serous cystadenoma (P<0.05). The serum CA125 of serous borderline tumor patients was (210.10±98.28) U/mL, which was significantly higher than that in patients with ovarian serous cystadenoma (P<0.05). The specificity, accuracy and positive predictive value of ultrasound combined with serum CA125 in the diagnosis of serous carcinoma were 90.57%, 87.50% and 81.48% respectively, which were significantly higher than those of ultrasound (P<0.05). Abdominal color Doppler ultrasound combined with CA125 has a good value in differential diagnosis of ovarian serous tumor.

Key words: abdominal color Doppler ultrasound, carbohydrate antigen 125, ovarian serous tumor, diagnostic value

DING Yingchun, BAO Lingling, YAN Xiaopeng. Study of Abdominal Color Doppler Ultrasound Combined with CA125 in the Diagnosis of Ovarian Serous Tumors[J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2022, 40(1): 133-137.

References

[1] Hatano Y, Hatano K, Tamada M, et al. A comprehensive review of ovarian serous carcinoma[J]. Advances in Anatomic Pathology, 2019, 26(5):329-339.
[2] Pan J B, Hu Y W, Sun S S, et al. Glycoproteomics-based signatures for tumor subtyping and clinical outcome prediction of high-grade serous ovarian cancer[J]. Nature Communications, 2020, 11(1):6139.
[3] 漆玖玲, 陆蓓蕾, 樊韵玲, 等. 卵巢浆液性交界性肿瘤与卵巢浆液性囊腺瘤超声特征对比分析[J]. 中国超声医学杂志, 2020, 36(10):934-937.
[4] 王慧. 131例卵巢交界性肿瘤临床分析[D]. 青岛:青岛大学, 2017.
[5] Alcázar J L, Guerriero S, Laparte C, et al. Diagnostic performance of transvaginal gray-scale ultrasound for specific diagnosis of benign ovarian cysts in relation to menopausal status[J]. Maturitas, 2011, 68(2):182-188.
[6] 毛佩敏, 刘晓艳. 血清CA125测定对卵巢高、低级别浆液性癌鉴别诊断价值的回顾性研究[J]. 检验医学, 2012, 27(7):592-594.
[7] Jones B P, Saso S, Farren J, et al. Ultrasound-guided laparoscopic ovarian wedge resection in recurrent serous borderline ovarian tumours[J]. International Journal of Gynecological Cancer, 2017, 27(9):1813-1818.
[8] Munakata S, Yamamoto T. Incidence of serous tubal intraepithelial carcinoma (STIC) by algorithm classification in serous ovarian tumor associated with PAX8 expression in tubal epithelia:A study of single institution in Japan[J]. International Journal of Gynecological Pathology, 2015, 34(1):9-18.
[9] May T, Stewart J M, Bernardini M Q, et al. The prognostic value of perioperative, pre-systemic therapy CA125 levels in patients with high-grade serous ovarian cancer[J]. International Journal of Gynecology & Obstetrics, 2018, 140(2):247-252.
[10] Moro F, Baima Poma C, Zannoni G F, et al. Imaging in gynecological disease(12):Clinical and ultrasound features of invasive and non-invasive malignant serous ovarian tumors:Serous ovarian tumors and ultrasound[J]. Ultrasound in Obstetrics & Gynecology, 2017, 50(6):788-799.
[11] De Blasis I, Tortorella L, Macchi C, et al. Intraoperative ultrasound diagnosis of metastatic lymph node in serous borderline ovarian tumor[J]. Ultrasound in Obstetrics & Gynecology, 2019, 54(4):562-563.
[12] Botesteanu D A, Lee J M, Levy D. Modeling the dynamics of high-grade serous ovarian cancer progression for transvaginal ultrasound-based screening and early detection[J]. PLoS One, 2016, 11(6):e0156661.
[13] Kaijser J. Towards an evidence-based approach for diagnosis and management of adnexal masses:Findings of the international ovarian tumour analysis (IOTA) studies[J]. Facts, Views Vision in ObGyn, 2015, 7(1):42-59.
[14] 焦婷婷, 孟繁君, 邸师红, 等. 血清附睾分泌蛋白4联合糖类抗原125在卵巢癌患者诊断及预后中的价值研究[J]. 国际免疫学杂志, 2017, 40(6):613-618.
[15] 李轲, 谢付静, 李军. 血清人附睾蛋白4联合糖类抗原125检测对浆液性卵巢癌的诊断价值[J]. 山东医药, 2016, 56(9):79-80.
[16] 杨堃, 魏佳希. HE4联合CA125检测在卵巢癌患者中的应用及诊断价值研究[J]. 中国性科学, 2019, 28(6):38-41.
[17] Choi J H, Sohn G S, Chay D B, et al. Preoperative serum levels of cancer antigen 125 and carcinoembryonic antigen ratio can improve differentiation between mucinous ovarian carcinoma and other epithelial ovarian carcinomas[J]. Obstetrics & Gynecology Science, 2018, 61(3):344-351.
[18] Li G, Huang W, Zhang L, et al. A prospective cohort study of early-pregnancy risk factors for gestational diabetes in polycystic ovarian syndrome[J]. Diabetes/Metabolism Research and Reviews, 2018, 34(5):e3003-e3304.
[19] Kucukgoz Gulec U, Paydas S, Guzel A B, et al. The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma[J]. Archives of Gynecology & Obstetrics, 2015, 292(4):923-929.
[20] 陈兰清. 彩色多普勒超声在诊断卵巢肿瘤中的应用[J]. 吉林医学, 2011, 32(10):1886-1888.